Yes, empagliflozin can and should be used in patients with chronic kidney disease.
Empagliflozin is recommended for adults with CKD who have an eGFR ≥20 mL/min/1.73 m², regardless of diabetes status, with the strength of recommendation increasing based on the patient's risk of CKD progression 1, 2.
eGFR Thresholds for Initiation
- Initiate empagliflozin when eGFR ≥20 mL/min/1.73 m² - this is the current evidence-based threshold supported by both the 2024 BMJ/KDIGO guidelines and the 2022 ADA/KDIGO consensus 1, 2
- The threshold was recently lowered from ≥30 mL/min/1.73 m² based on robust evidence from the EMPA-KIDNEY trial, which demonstrated efficacy and safety in patients with eGFR as low as 20 mL/min/1.73 m² 2, 3
- Continue empagliflozin even if eGFR falls below 20 mL/min/1.73 m² after initiation - the drug provides ongoing kidney protection and does not need to be stopped unless kidney replacement therapy is initiated 2
Risk-Stratified Recommendations
The strength of recommendation varies by CKD progression risk 1:
- Very high risk (e.g., high albuminuria, rapidly declining eGFR): Strong recommendation - empagliflozin reduces all-cause mortality by 48 per 1000 and kidney failure by 58 per 1000 patients
- High risk: Strong recommendation
- Moderate risk: Weak recommendation
- Low risk: Weak recommendation
Key Benefits Across All CKD Stages
Empagliflozin provides consistent benefits regardless of baseline kidney function 3, 4:
- Reduces kidney disease progression by 28% (HR 0.72) - defined as end-stage kidney disease, sustained eGFR decline ≥40%, eGFR <10 mL/min/1.73 m², or renal death 3
- Slows eGFR decline by 50% - chronic slope reduced from -2.75 to -1.37 mL/min/1.73 m²/year after the initial 2-month dip 4
- Reduces all-cause hospitalizations by 14% (HR 0.86), with particular benefit for cardiovascular, renal, and metabolic admissions 5
- Benefits persist for up to 12 months after discontinuation - the protective effects continue even after stopping the medication 6
Critical Point About Albuminuria
Do not use albuminuria level alone to decide whether to prescribe empagliflozin 4. While the absolute benefit is larger in patients with higher albuminuria, the relative benefit is actually greater in those with lower albuminuria:
- Patients with uACR <30 mg/g: 86% reduction in chronic eGFR slope
- Patients with uACR ≥2000 mg/g: 29% reduction in chronic eGFR slope
- The drug works across the entire spectrum of albuminuria, including those with minimal proteinuria 4
Diabetes Status Is Irrelevant
Empagliflozin works equally well in patients with or without diabetes 1, 3. The EMPA-KIDNEY trial included both populations and showed consistent benefits, making this a kidney-protective medication rather than just a diabetes drug.
Expected Initial eGFR Dip
Anticipate an acute 2.12 mL/min/1.73 m² drop in eGFR (approximately 6% dip) within the first 2 months 4. This is:
- Hemodynamic and reversible - not actual kidney damage
- Expected and beneficial - reflects reduced intraglomerular pressure
- Not a reason to discontinue - the long-term kidney protection far outweighs this initial dip
Safety Considerations
Monitor for but don't overreact to 2:
- Volume depletion: Consider proactive diuretic dose reduction in high-risk patients; hold during acute illness
- Genital mycotic infections: Counsel on hygiene
- Diabetic ketoacidosis: Rare, but educate patients on sick-day protocols and maintain at least low-dose insulin in insulin-requiring patients
- Hypoglycemia: Adjust insulin or sulfonylurea doses as needed
The FDA label confirms that empagliflozin exposure increases modestly in severe renal impairment (66% higher AUC with eGFR <30), but this does not translate to increased harm 7.
Practical Dosing
- Standard dose: 10 mg once daily - this was the dose used in EMPA-KIDNEY 3
- No dose adjustment needed based on eGFR
- Can be taken with or without food 7
Common Pitfall to Avoid
Do not withhold empagliflozin from patients with advanced CKD (eGFR 20-29 mL/min/1.73 m²) thinking it won't work - this population actually derives substantial benefit, with evidence strongest when they also have albuminuria or heart failure, though benefits extend to all patients in this eGFR range 2.